Introducing the TriNav FLX Infusion System by TriSalus Life Sciences

TriSalus Life Sciences has recently unveiled the TriNav FLX infusion system.

According to a recent company press release, while the TriNav FLX infusion system preserves the well - regarded pressure - enabled drug delivery (PEDD) advantages that are inherent in its existing products, it marks a significant design leap forward. The new system is equipped with a flexible material at the distal end that is twice as long as before. This enhancement enables smoother navigation through more convoluted blood vessels.

Here are some of the key features of the TriNav FLX infusion system:

• Trackability: The increased flexibility of the distal end facilitates better navigation through challenging vascular paths.
• Reduction in Force: In laboratory benchtop models, the TriNav FLX showed a 28% decrease in the force required during navigation when compared to the standard TriNav design.

Mary Szela, the chief executive officer of TriSalus Life Sciences, expressed her enthusiasm, saying, "We're thrilled to enhance our TriNav product line with the launch of the TriNav FLX infusion system. With the TriNav FLX, we now provide a full - fledged set of advanced technologies. These are specifically crafted to assist interventional radiologists in maneuvering through a broad spectrum of peripheral vessel sizes and complexities. Our ongoing investment in product line innovation highlights our dedication to expanding the accessibility of pressure - enabled drug delivery to a larger number of patients.

What's more, the TriNav FLX is eligible for reimbursement under HCPCS Code C8004 for simulation (or mapping) and C9797 for treatment procedures. This dual - coverage option empowers clinicians to utilize the TriNav FLX for both the planning and delivery stages in radioembolization, thereby promoting greater precision and continuity of patient care."